上海泰坦科技股份有限公司关于公司与关联方共同投资暨关联交易的公告

Core Viewpoint - Titan Technology and its affiliate, Shanghai Titan HeYuan Phase I Private Investment Fund, plan to jointly invest in Titan MicroSource Testing Technology Co., Ltd, increasing its registered capital from 10 million to 50 million yuan, with Titan holding 70% and the fund holding 30% after the investment [2][4]. Group 1: Investment Overview - The investment aims to enhance the overall development strategy and business needs of the company [4]. - The registered capital of MicroSource Testing will increase by 40 million yuan, with Titan contributing 25 million yuan and the fund contributing 15 million yuan [2][4]. - The funding for Titan's investment will come from its own funds [2]. Group 2: Transaction Details - The investment constitutes a related party transaction but does not qualify as a major asset restructuring under relevant regulations [3][8]. - The transaction has been approved by the company's board and does not require shareholder approval [3][8][20]. - In the past 12 months, related party transactions have not exceeded 1% of the company's audited total assets or market value, and have not surpassed 30 million yuan [3][9]. Group 3: Target Company Information - MicroSource Testing was established in February 2025 and focuses on laboratory services, including verification and testing services, equipment leasing, and key component R&D [12]. - The company has not yet commenced operations and will rely on Titan for initial support, including technical management and resources [12]. - As the business expands, MicroSource Testing will develop its own operational and technical teams [12]. Group 4: Investment Rationale and Impact - The joint investment is intended to improve the company's business layout and integrate resources for enhanced competitive advantage [18]. - The investment will not affect the company's normal operations or independence, as both parties are using their own funds [18]. - The transaction is based on voluntary, fair, and reasonable principles, ensuring no harm to the interests of the company or its shareholders [18][20].